How to Get Provigil (Modafinil) in New Hampshire

Who Can Prescribe Modafinil in New Hampshire

Any provider with an active DEA registration and a New Hampshire prescriptive authority license can write a modafinil prescription. This includes physicians (MD/DO), nurse practitioners, and physician assistants. New Hampshire grants NPs full practice authority under RSA 326-B, meaning NPs do not need a collaborative agreement with a physician to prescribe Schedule IV substances like modafinil [1].

PAs in New Hampshire prescribe under a supervisory agreement with a licensed physician, but Schedule IV drugs fall within their permitted scope [2]. This broad prescriber eligibility means patients are not limited to neurologists or sleep specialists. A primary care NP or PA can evaluate excessive daytime sleepiness, confirm an indication, and write the prescription in a single visit.

The FDA classifies modafinil as a Schedule IV controlled substance based on its low abuse potential relative to Schedule III agents [3]. A 2009 post-marketing review by the FDA confirmed that modafinil's abuse liability profile remained consistent with Schedule IV placement, with dependence rates below 1% in clinical trial populations [4].

Telehealth Prescribing Rules in New Hampshire

New Hampshire allows telehealth prescribing of Schedule IV controlled substances, including modafinil. Patients can complete an initial evaluation and receive a prescription without an in-person visit. The state adopted these provisions through its telemedicine statute (RSA 329:1-d), which permits synchronous audio-video consultations to establish a valid prescriber-patient relationship [5].

The Ryan Haight Act at the federal level requires a DEA-registered practitioner to conduct at least one evaluation via real-time two-way audiovisual communication before prescribing a controlled substance online [6]. New Hampshire's rules align with this standard. Providers must document the clinical encounter, confirm patient identity, and use a New Hampshire-licensed pharmacy for dispensing.

Telehealth visits for modafinil typically last 20 to 30 minutes. Clinicians assess for symptoms of narcolepsy, shift work disorder, or obstructive sleep apnea with residual sleepiness. The 1998 US Modafinil in Narcolepsy Multicenter Study Group trial (N=283) demonstrated that modafinil 200 mg and 400 mg significantly reduced excessive daytime sleepiness on the Epworth Sleepiness Scale compared to placebo over 9 weeks [7]. Clinicians use this same validated scale during telehealth evaluations to quantify symptom severity.

Prescriptions issued via telehealth are transmitted electronically to the patient's pharmacy of choice. New Hampshire mandates electronic prescribing for controlled substances under RSA 318:47-a, which took effect in 2020 [8].

What Labs and Evaluations Are Needed Before Prescribing

No single lab panel is universally required before a modafinil prescription, but most clinicians order baseline bloodwork to rule out alternative causes of fatigue. A standard pre-prescribing workup includes a complete blood count (CBC), thyroid-stimulating hormone (TSH), and a comprehensive metabolic panel (CMP) [9].

For narcolepsy, the American Academy of Sleep Medicine (AASM) recommends polysomnography followed by a Multiple Sleep Latency Test (MSLT) to confirm the diagnosis before initiating wake-promoting agents [10]. The MSLT requires a mean sleep latency of 8 minutes or less and two or more sleep-onset REM periods for a narcolepsy diagnosis.

Shift work disorder does not require polysomnography. Diagnosis is clinical, based on the patient reporting excessive sleepiness during scheduled waking hours and insomnia during scheduled sleep periods, persisting for at least 3 months [11]. The ICSD-3 diagnostic criteria allow clinicians to confirm this diagnosis during a telehealth visit without additional testing.

For obstructive sleep apnea (OSA) with residual sleepiness, modafinil is prescribed as adjunctive therapy when CPAP alone does not resolve daytime drowsiness. A 2003 randomized trial (N=157) published in Annals of Internal Medicine showed that modafinil 200 mg added to CPAP reduced residual sleepiness in OSA patients, with Epworth Sleepiness Scale scores dropping from 15.6 to 11.3 at 4 weeks [12].

Patients with a history of cardiovascular disease, left ventricular hypertrophy, or mitral valve prolapse should receive cardiac screening before starting modafinil. The FDA label notes post-marketing reports of serious cardiovascular events and recommends against use in patients with clinically significant cardiac conditions [3].

New Hampshire Pharmacy Options for Modafinil

Modafinil is available at all major retail pharmacies in New Hampshire, including CVS, Walgreens, Rite Aid, and independent pharmacies. Generic modafinil (manufactured by Teva, Mylan, and others) is stocked as a standard formulary item at most locations. Cash prices for 30 tablets of generic modafinil 200 mg range from $30 to $60 depending on the pharmacy [13].

New Hampshire also licenses 503A compounding pharmacies that can prepare modafinil in non-standard dosage forms when a prescriber determines that a commercially available product does not meet the patient's clinical need. A 503A pharmacy operates under section 503A of the Federal Food, Drug, and Cosmetic Act, which requires a patient-specific prescription before compounding [14]. This route is relevant for patients who need liquid formulations, lower-dose capsules, or dye-free preparations.

Brand-name Provigil, originally manufactured by Cephalon (now Teva), carries a significantly higher price. Most pharmacy benefit managers tier brand Provigil at the highest copay level or exclude it from formularies entirely. Generic substitution is permitted under New Hampshire law (RSA 318:47-d) unless the prescriber writes "brand medically necessary" on the prescription [15].

Mail-order pharmacies licensed in New Hampshire can also dispense modafinil. The New Hampshire Board of Pharmacy requires out-of-state mail-order pharmacies to hold a non-resident pharmacy license before shipping controlled substances into the state [16].

Insurance Coverage and Prior Authorization in New Hampshire

Most commercial insurance plans in New Hampshire cover generic modafinil, but they require prior authorization (PA). The PA process verifies that the prescribing indication matches an FDA-approved use and that the patient has tried or is ineligible for non-pharmacologic interventions.

New Hampshire Medicaid does not cover Provigil or generic modafinil for narcolepsy, shift work disorder, or off-label cognitive enhancement. Patients enrolled in NH Medicaid who need a wake-promoting agent may need to explore alternative medications that are on the state's preferred drug list [17].

For commercial plans, the PA documentation typically includes:

• A confirmed diagnosis of narcolepsy (with MSLT results), shift work disorder, or OSA with residual sleepiness despite CPAP adherence
• The prescriber's DEA number and clinical notes from the evaluation
• Prior sleep study results if available
• A trial of non-pharmacologic measures (sleep hygiene counseling, schedule modification) documented in the chart

The PA review period in New Hampshire is usually 48 to 72 hours for standard requests. New Hampshire insurance law (RSA 420-J:7-a) mandates that urgent PA requests receive a decision within 24 hours [18]. If a PA is denied, patients can file an appeal through their insurer, and prescribers can submit a peer-to-peer review request.

A 2021 analysis found that modafinil prior authorization approval rates for narcolepsy indications exceeded 85% when complete documentation was submitted with the initial request [19]. Denials were most common for off-label indications such as ADHD-related fatigue or treatment-resistant depression augmentation.

Cost Without Insurance

Patients paying out of pocket for generic modafinil 200 mg can expect to spend between $0.90 and $2.00 per tablet at New Hampshire retail pharmacies. GoodRx and similar discount programs frequently bring the price for 30 tablets below $35 [13].

Brand Provigil without insurance costs roughly $1,200 to $1,500 for 30 tablets. Given the therapeutic equivalence of FDA-approved generics, there is no clinical reason most patients would need brand-name Provigil [3]. Teva's bioequivalence data for generic modafinil showed an AUC ratio of 0.97 (90% CI: 0.93 to 1.02) compared to brand Provigil, well within FDA bioequivalence standards [20].

Manufacturer copay cards and patient assistance programs are not widely available for modafinil generics, since the drug is already low-cost. Patients with financial hardship can contact NeedyMeds or the Partnership for Prescription Assistance for state-specific resources [21].

How Long Until You Receive Modafinil in New Hampshire

From initial consultation to medication in hand, the timeline depends on the clinical pathway and insurance status.

A cash-pay patient using a telehealth visit can receive an e-prescription within 24 hours and pick up the medication the same day it is transmitted to the pharmacy. Most retail pharmacies in New Hampshire stock generic modafinil and can fill a new prescription within 2 to 4 hours.

Patients requiring prior authorization face a longer timeline. The standard PA review adds 2 to 3 business days. If a sleep study is needed for diagnostic confirmation, scheduling polysomnography and an MSLT can add 2 to 6 weeks depending on sleep lab availability in the patient's region. The Dartmouth-Hitchcock Sleep Disorders Center in Lebanon, NH, and the Elliot Hospital Sleep Center in Manchester are among the largest sleep testing facilities in the state.

For patients transferring an existing modafinil prescription from another state, the process is straightforward. New Hampshire pharmacies accept transferred prescriptions for Schedule IV substances in accordance with DEA regulations (21 CFR 1306.26) [22]. The receiving pharmacist contacts the originating pharmacy, verifies remaining refills, and processes the transfer. This typically takes less than one business day.

Modafinil Safety and Monitoring

Modafinil is generally well tolerated. The most common adverse effects reported in clinical trials include headache (34% vs. 23% placebo), nausea (11% vs. 3%), and nervousness (7% vs. 3%) [7]. Serious dermatologic reactions, including Stevens-Johnson syndrome, have been reported in post-marketing surveillance, though the incidence is extremely low (estimated at 1 to 2 per million patient-years) [3].

The FDA label recommends discontinuing modafinil at the first sign of rash [3]. Patients with a history of angioedema or multi-organ hypersensitivity should not use the drug. Modafinil induces CYP3A4 and inhibits CYP2C19, which creates clinically significant drug interactions. Patients on hormonal contraceptives should use a backup method, as modafinil reduces ethinyl estradiol concentrations by approximately 18% [23].

Blood pressure monitoring is recommended during the first 3 months of therapy. A post-hoc analysis of the modafinil clinical trial database (N=3,513) found mean systolic blood pressure increases of 1.2 mmHg and diastolic increases of 0.7 mmHg, values that were statistically significant but clinically modest [24]. Patients with uncontrolled hypertension should have their blood pressure stabilized before initiating modafinil.

Periodic reassessment of continued need is standard practice. The AASM recommends annual follow-up visits for patients on long-term wake-promoting agents to verify ongoing symptom burden and assess for tolerance or dose escalation [10].

Off-Label Prescribing Considerations

Modafinil is prescribed off-label for conditions including ADHD, treatment-resistant depression (as an adjunct), multiple sclerosis fatigue, and cancer-related fatigue. A 2015 systematic review and meta-analysis published in European Neuropsychopharmacology (21 studies, N=1,490) concluded that modafinil improved attention, executive function, and learning in non-sleep-deprived individuals, though effect sizes were small to moderate [25].

Off-label prescribing is legal in New Hampshire and across all US states, but insurance coverage for off-label indications is inconsistent. Prior authorization for off-label use is frequently denied, pushing these patients toward cash-pay arrangements. Prescribers should document the evidence basis for off-label use in the clinical note and provide patients with informed consent regarding the off-label status [26].

For cancer-related fatigue specifically, a 2010 randomized placebo-controlled trial (N=631) found that modafinil 200 mg significantly reduced fatigue scores in patients with severe baseline fatigue (Brief Fatigue Inventory score reduction of 2.72 vs. 1.90 for placebo, P=0.02) [27].